ArticleTranslational stroke research2011
Recombinant T cell receptor ligands improve outcome after experimental cerebral ischemia.
Article in Translational stroke research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis.Scientific reports · 2016Pooled it
- Bystanders or not? Microglia and lymphocytes in aging and stroke.Neural regeneration research · 2023Review
- Microglia and Macrophages in Neuroprotection, Neurogenesis, and Emerging Therapies for Stroke.Cells · 2021Review
- T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights.Frontiers in immunology · 2021Review
- Targeting Brain-spleen Crosstalk After Stroke: New Insights Into Stroke Pathology and Treatment.Current neuropharmacology · 2021Review
- The splenic response to stroke: from rodents to stroke subjects.Journal of neuroinflammation · 2018Review
- Review
- Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Neurochemistry international · 2017Review
- Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Neurochemistry international · 2017Article
- Sex differences in the immune response to experimental stroke: Implications for translational research.Journal of neuroscience research · 2017Review
- Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion.Translational stroke research · 2016Article
- So you think you can jump? A novel long jump assessment to detect deficits in stroked mice.Journal of neuroscience methods · 2015Article
- Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke.Translational stroke research · 2015Article
- Article
- Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke.Translational stroke research · 2014Article
- A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.Metabolic brain disease · 2014Article
- Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Frontiers in cellular neuroscience · 2014Article
- A novel hypothesis: regulatory B lymphocytes shape outcome from experimental stroke.Translational stroke research · 2012Article
- Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.Metabolic brain disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
A key target for novel stroke therapy is the regulation of post-ischemic inflammatory mechanisms. Recent evidence emphasizes the role of T lymphocytes of differing subtypes in the evolution is ischemic brain damage. We have recently demonstrated the benefit of myelin antigen-specific immunodulatory agents known as recombinant T cell receptor ligands (RTLs) in a standard murine model of focal stroke. The aim of the current study was to extend this initial observation to RTL treatment in a therapeutically relevant timing after middle cerebral artery occlusion (MCAO) and verify functional benefit to complement histological outcome measures. We observed that the administration of mouse-specific RTL551 reduced infarct size and improved sensorimotor outcome when administered within a 3 h post-ischemic therapeutic window. RTL551 treatment reduced cortical, caudate putamen, and total infarct volume as compared to vehicle-treated mice. Using a standard behavioral testing repertoire, we observed that RTL551 reduced sensorimotor impairment 3 days after MCAO. Humanized RTL1000 (HLA-DR2 moiety linked to hMOG-35-55 peptide) also reduced infarct size in HLA-DR2 transgenic mice. These data indicate that this neuroantigen-specific immunomodulatory agent reduces damage when administered in a therapeutically relevant reperfusion timeframe.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.